Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of treating her2-positive cancers using pd-1 axis binding antagonists and Anti-her2 antibodies

a technology of pd-1 axis binding antagonist and anti-her2 antibody, which is applied in the field of her2-positive cancer treatment, can solve the problems of refractory, exhaustion or tolerance to foreign antigens, etc., and achieve the effects of enhanced priming, activation, proliferation and/or cytolytic activity

Inactive Publication Date: 2017-01-12
GENENTECH INC
View PDF5 Cites 62 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes antibodies that target specific molecules, such as PD-1 and HER2, and a combination of these antibodies. The antibodies are modified to have reduced effector function, and the combination treatment results in enhanced activity of CD8 T cells, with increased number and cytolytic activity. The treatment also suppresses Treg function and decreases T cell exhaustion. Overall, the patent provides a technical solution for improving the effectiveness of immunotherapy treatment for cancer and other diseases.

Problems solved by technology

In the absence of co-stimulation, T-cells can become refractory to antigen stimulation, do not mount an effective immune response, and further may result in exhaustion or tolerance to foreign antigens.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating her2-positive cancers using pd-1 axis binding antagonists and Anti-her2 antibodies
  • Methods of treating her2-positive cancers using pd-1 axis binding antagonists and Anti-her2 antibodies
  • Methods of treating her2-positive cancers using pd-1 axis binding antagonists and Anti-her2 antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

HER2 T Cell Dependent Bispecific Antibody (HER2-TDB) for Treatment of HER2 Positive Cancers

[0352]Based on recent clinical success of tumor immunotherapies that block immune suppressive mechanisms to restore T cell function, there is a profound interest in the clinical development of T cell targeted therapies. To meet this demand, described herein is a trastuzumab-based HER2 T cell dependent bispecific antibody (HER2-TDB). This full-length human IgG format bispecific antibody conditionally activated T cells resulting in lysis of HER2 expressing cancer cells at low picomolar concentrations Importantly, HER2-TDB was able to eliminate cells refractory to currently approved HER2 therapies. The potent anti-tumor activity of HER2-TDB was demonstrated using four model systems including MMTV-huHER2 and huCD3 transgenic mice. These results demonstrated inhibitory effect of PD-L1 expression on the activity of bispecific T cell recruiting antibodies. This resistance mechanism was reversed by an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
tumor shrinkageaaaaaaaaaa
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
Login to View More

Abstract

The invention provides compositions and methods for treating HER2-postitive cancers. The method comprising administering a PD-1 axis binding antagonist and an antibody that targets HER2.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the priority benefit of U.S. Provisional Application No. 61 / 917,264, filed Dec. 17, 2013, which is hereby incorporated by reference in its entirety.SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE[0002]The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 146392022840 SeqList.txt, date recorded: Dec. 16, 2014, size: 37 KB).FIELD OF THE INVENTION[0003]This invention relates to methods of treating HER2-positive cancers by administering a PD-1 axis binding antagonist and an anti-HER2 antibody.BACKGROUND OF THE INVENTION[0004]The provision of two distinct signals to T-cells is a widely accepted model for lymphocyte activation of resting T lymphocytes by antigen-presenting cells (APCs). Lafferty et al, Aust. J. Exp. Biol. Med. Sci 53: 27-42 (1975). This model further provides for the discriminati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/32A61K39/395A61K45/06C07K16/28C07K16/30
CPCC07K16/32C07K2317/92C07K16/2809C07K16/3015C07K16/3023C07K16/3069C07K16/3038C07K16/303A61K45/06A61K39/3955C07K16/2827C07K2317/76C07K2317/31C07K2317/526C07K2317/524C07K2317/41A61K2039/507C07K16/2818C07K16/2863A61K31/337A61K39/395C07K2317/94C07K2317/56C07K2317/52C07K2317/73C07K2317/24A61K2300/00A61K2039/505A61K39/39558A61P35/00A61P37/02A61P37/04A61P43/00A61K31/282C07K16/2803A61K47/643C07K16/30A61K31/555A61K2039/545A61K2039/54
Inventor DENNIS, MARK S.EBENS, ALLENIRVING, BRYANJUNTTILA, TEEMU T.LI, JI
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com